Alembic Pharmaceuticals Limited has secured a major regulatory victory, receiving final approval from the US Food and Drug Administration (USFDA) for its generic levothyroxine sodium tablets. The approval clears the way for the company to market its drug across a comprehensive range of twelve different strengths, stretching from 25 mcg up to 300 mcg.
According to a recent regulatory filing, Alembic’s Abbreviated New Drug Application (ANDA) is therapeutically equivalent to the reference listed drug, Synthroid, which is manufactured by AbbVie, Inc. Levothyroxine sodium is primarily utilized as a vital hormone replacement therapy for patients suffering from various forms of congenital or acquired hypothyroidism, including primary, secondary, and tertiary variations. Beyond its core function as a thyroid hormone substitute, the medication is also indicated as an essential adjunct therapy alongside surgery and radioiodine treatment to manage thyrotropin-dependent well-differentiated thyroid cancer.
This regulatory milestone positions Alembic to tap into a highly lucrative pharmaceutical segment. Citing industry data from IQVIA, the company noted that the market size for levothyroxine sodium tablets is estimated at a staggering $1,869 million for the twelve months ending March 2026. With this green light from the USFDA, Alembic is well-positioned to strengthen its presence in the competitive US healthcare market by providing patients with an affordable, high-quality generic alternative for thyroid management.
